Creso Pharma (ASX:CPH)
- Ticker 2:OTC:COPHF
- CEO:Dr. Miriam Wernli
Creso Pharma (ASX:CPH) Company Overview
Founded in 2015, Creso Pharma (ASX:CPH) has developed, registered, and commercialised several cannabis-based pharmaceutical products for both human and animal health care in Australia, Slovakia, and Switzerland.
Aside from the development of cannabis-based medicine, Creso Pharma also has its' hand in hemp growing operations, outsourced CBD extraction, and the sale of CBD-based products.
The biotech company's strong focus on CBD has left it well positioned to move in on the growing pet market, which is estimated to be worth $72 billion in the US.
Animal health is just one of five areas that the company's business model focuses on, along with lifestyle products, nutraceuticals, topicals, and therapeutics. It is currently in the process of developing new medicines through its' R&D base in Switzerland, while also maintaining growing and cultivation facilities in Columbia and Canada.
The company was recently sold to PharmaCielo for $122 million, and in the process, became the first Australian Cannabis Company to be acquired.